Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID ‐19 patients with type 2 diabetes:   A target trial emulation study

Eric Y. F. Wan; Zoey C. T. Wong; Vincent K. C. Yan; Celine S. L. Chui; Francisco T. T. Lai; Xue Li; Ian C. K. Wong; Esther W. Y. Chan

doi:10.1111/dom.15830

Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID ‐19 patients with type 2 diabetes: A target trial emulation study

Eric Y. F. Wan, Zoey C. T. Wong, Vincent K. C. Yan, Celine S. L. Chui, Francisco T. T. Lai, Xue Li, Ian C. K. Wong^*, Esther W. Y. Chan^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Aims: To compare the effectiveness of molnupiravir and nirmatrelvir‐ritonavir for non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes (T2DM). Materials and Methods: Territory‐wide electronic health records in Hong Kong were used to perform target trial emulation using a sequential trial approach. Patients (1) aged ≥18 years, (2) with T2DM, (3) with COVID‐19 infection, and (4) who received molnupiravir or nirmatrelvir‐ritonavir within 5 days of infection between 16 March 2022 and 31 December 2022 in non‐hospital and hospital settings were included. Molnupiravir and nirmatrelvir‐ritonavir initiators were matched using one‐to‐one propensity‐score matching and followed for 28 days. Risk of outcomes was compared between groups by Cox regression adjusted for baseline characteristics. Subgroup analyses were performed on age (

Original language	English
Journal	Diabetes, Obesity and Metabolism
Early online date	7 Aug 2024
DOIs	https://doi.org/10.1111/dom.15830
Publication status	E-pub ahead of print - 7 Aug 2024

Bibliographical note

Published CC BY NC

Publisher Copyright:
© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Data Access Statement

Data are not available as the data custodians (the Hospital Authority and the Department of Health of Hong Kong SAR) have not given permission for sharing due to patient confidentiality and privacy concerns. Local academic institutions, government departments, or non-governmental organizations may apply for the access to data through the Hospital Authority's data sharing portal (https://www3.ha.org.hk/data).

Keywords

effectiveness
pharmacoepidemiology
real-world evidence
type 2 diabetes

Access to Document

10.1111/dom.15830

Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation studyFinal published version, 1.08 MBLicence: CC BY-NC 4.0

Cite this

Wan, E. Y. F., Wong, Z. C. T., Yan, V. K. C., Chui, C. S. L., Lai, F. T. T., Li, X., Wong, I. C. K., & Chan, E. W. Y. (2024). Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID ‐19 patients with type 2 diabetes: A target trial emulation study. Diabetes, Obesity and Metabolism. Advance online publication. https://doi.org/10.1111/dom.15830

@article{6e9bf224e2f94a4ca0785b3eda01308b,

title = "Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID ‐19 patients with type 2 diabetes: A target trial emulation study",

abstract = "Aims: To compare the effectiveness of molnupiravir and nirmatrelvir‐ritonavir for non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes (T2DM). Materials and Methods: Territory‐wide electronic health records in Hong Kong were used to perform target trial emulation using a sequential trial approach. Patients (1) aged ≥18 years, (2) with T2DM, (3) with COVID‐19 infection, and (4) who received molnupiravir or nirmatrelvir‐ritonavir within 5 days of infection between 16 March 2022 and 31 December 2022 in non‐hospital and hospital settings were included. Molnupiravir and nirmatrelvir‐ritonavir initiators were matched using one‐to‐one propensity‐score matching and followed for 28 days. Risk of outcomes was compared between groups by Cox regression adjusted for baseline characteristics. Subgroup analyses were performed on age (",

keywords = "effectiveness, pharmacoepidemiology, real-world evidence, type 2 diabetes",

author = "Wan, {Eric Y. F.} and Wong, {Zoey C. T.} and Yan, {Vincent K. C.} and Chui, {Celine S. L.} and Lai, {Francisco T. T.} and Xue Li and Wong, {Ian C. K.} and Chan, {Esther W. Y.}",

note = "Published CC BY NC Publisher Copyright: {\textcopyright} 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.",

year = "2024",

month = aug,

day = "7",

doi = "10.1111/dom.15830",

language = "English",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID ‐19 patients with type 2 diabetes

T2 - A target trial emulation study

AU - Wan, Eric Y. F.

AU - Wong, Zoey C. T.

AU - Yan, Vincent K. C.

AU - Chui, Celine S. L.

AU - Lai, Francisco T. T.

AU - Li, Xue

AU - Wong, Ian C. K.

AU - Chan, Esther W. Y.

PY - 2024/8/7

Y1 - 2024/8/7

N2 - Aims: To compare the effectiveness of molnupiravir and nirmatrelvir‐ritonavir for non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes (T2DM). Materials and Methods: Territory‐wide electronic health records in Hong Kong were used to perform target trial emulation using a sequential trial approach. Patients (1) aged ≥18 years, (2) with T2DM, (3) with COVID‐19 infection, and (4) who received molnupiravir or nirmatrelvir‐ritonavir within 5 days of infection between 16 March 2022 and 31 December 2022 in non‐hospital and hospital settings were included. Molnupiravir and nirmatrelvir‐ritonavir initiators were matched using one‐to‐one propensity‐score matching and followed for 28 days. Risk of outcomes was compared between groups by Cox regression adjusted for baseline characteristics. Subgroup analyses were performed on age (

AB - Aims: To compare the effectiveness of molnupiravir and nirmatrelvir‐ritonavir for non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes (T2DM). Materials and Methods: Territory‐wide electronic health records in Hong Kong were used to perform target trial emulation using a sequential trial approach. Patients (1) aged ≥18 years, (2) with T2DM, (3) with COVID‐19 infection, and (4) who received molnupiravir or nirmatrelvir‐ritonavir within 5 days of infection between 16 March 2022 and 31 December 2022 in non‐hospital and hospital settings were included. Molnupiravir and nirmatrelvir‐ritonavir initiators were matched using one‐to‐one propensity‐score matching and followed for 28 days. Risk of outcomes was compared between groups by Cox regression adjusted for baseline characteristics. Subgroup analyses were performed on age (

KW - effectiveness

KW - pharmacoepidemiology

KW - real-world evidence

KW - type 2 diabetes

UR - https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15830

UR - http://www.scopus.com/inward/record.url?scp=85200549223&partnerID=8YFLogxK

U2 - 10.1111/dom.15830

DO - 10.1111/dom.15830

M3 - Article

SN - 1462-8902

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

ER -